Ryvu Therapeutics Sa
Clinical trials sponsored by Ryvu Therapeutics Sa, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for Tough-to-Treat lymphoma: Two-Drug combo enters Mid-Stage trial Results expected Dec 2026 (estimated)
- Cancer drug RVU120 gets extended trial for ongoing patients Results expected Dec 2026 (estimated)
- Two-Drug combo targets leukemia that outsmarted its first treatment Results expected Aug 2027 (estimated)
-
Two-Drug combo targets leukemia that outsmarted its first treatment
Disease control Recruiting nowResearchers are testing whether adding an experimental drug called RVU120 to venetoclax can help adults with acute myeloid leukemia (AML) that has come back or stopped responding to earlier venetoclax-based treatment. The trial enrolls about 98 adults who have already failed a hy…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for Tough-to-Treat lymphoma: Two-Drug combo enters Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial is testing a new drug called MEN1703, both alone and combined with another drug called glofitamab, in 178 adults with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The study aims to see if the drugs…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC